Skip to main content

DaVita Value Stock - Dividend - Research Selection

Davita

ISIN: US23918K1088 , WKN: 897914

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Top Medical Stocks To Hedge Against The September Effect

2024-09-04
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

BofA’s global contenders and defenders list

2024-09-04
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Nvidia Gets Spanked To Start September, But This Stock Stays Fresh

2024-09-03
A roller-coaster summer continues for Nvidia stock, while Freshpet leads a brigade of breakout stocks to watch.

Nvidia Flails As Freshpet, ServiceNow Lead 7 Stocks To Watch

2024-09-03
A roller-coaster summer continues for Nvidia stock, while Freshpet leads a brigade of breakout stocks to watch.

DaVita Rallies 44% Year to Date: What's Driving the Stock?

2024-09-02
DVA's shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.

Insider trades: Notables buy and sell by significant shareholders, executives and directors

2024-09-02
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

DaVita HealthCare (DVA) is a Great Momentum Stock: Should You Buy?

2024-08-30
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Catalent's Stock Gains on Q4 Earnings Beat, Gross Margin Up

2024-08-30
CTLT's solid segmental results led to an encouraging fiscal fourth-quarter performance, driving up share prices in after-hours trading.

Best Value Stocks to Buy for August 30th

2024-08-30
RCMT, AIZ and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 30, 2024.

Insider Sale: CFO and Treasurer Joel Ackerman Sells 68,769 Shares of DaVita Inc (DVA)

2024-08-30
On August 28, 2024, Joel Ackerman, the Chief Financial Officer and Treasurer of DaVita Inc (NYSE:DVA), executed a significant transaction by selling 68,769 shares of the company. The sale was documented in a recent SEC Filing. Following this transaction, the insider now owns 106,741 shares of DaVita Inc.